Post Profile






IL-34: New, possible target to tackle drug-resistant cancer cells

Chemoresistant lung cancer cells suppress immune functions and strengthen resistance to chemotherapy by producing interleukin-34 (IL-34)—a type of cytokine, a team of researchers has discovered.
read more

share

Related Posts


Researchers discover targeted way to treat ovarian cancer

Health : Medical News Today

Researchers at Women & Infants Hospital of Rhode Island have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy. Th...

New immunotherapy drug outperforms chemotherapy for a form of lung cancer

Health : The Checkup

CHICAGO — A new drug that unleashes the body's immune system on cancer cells performed better than a traditional chemotherapy agent in fighting an advanced form of lung cancer, researchers reported Friday. The new drug was also less...

Newly Discovered Immune Cell Type Protects Against Lung Infections During Chemotherapy

Health : Newswise Medical News

St. Jude Children's Research Hospital scientists have discovered a previously unrecognized form of macrophage in mice; the immune cells survived chemotherapy and protected against life-threatening lung infections.

Method discovered that allows native immune cells to launch an attack on pancreas cancer

Health : Medical News Today

Pancreas cancer is notoriously impervious to treatment and resists both chemotherapy and radiotherapy. It has also been thought to provide few targets for immune cells, allowing tumors to grow unchecked. But new research from Fred H...

Crizotinib's Superiority To Chemotherapy For ALK-positive Lung Cancer Confirmed; First Crizotinib Resistance In ROS1-positive Lung Tumor

Health : Medical News Today

Research teams led by Massachusetts General Hospital (MGH) Cancer Center investigators are publishing two important studies regarding use of the targeted cancer drug crizotinib for treatment of advanced lung cancer driven by specifi...

Comments


Copyright © 2016 Regator, LLC